BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $159,012 | -16.6% | 2,336 | 0.0% | 0.01% | -7.1% |
| Q2 2023 | $190,688 | +10.0% | 2,336 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $173,308 | +48.1% | 2,336 | +467.0% | 0.01% | +100.0% |
| Q3 2022 | $117,000 | -44.0% | 412 | -31.9% | 0.01% | -41.7% |
| Q2 2022 | $209,000 | -52.6% | 605 | -40.7% | 0.01% | -45.5% |
| Q1 2022 | $441,000 | +103.2% | 1,020 | +143.4% | 0.02% | 0.0% |
| Q4 2021 | $217,000 | -62.3% | 419 | -64.7% | 0.02% | -26.7% |
| Q3 2021 | $575,000 | +9.1% | 1,188 | +1.5% | 0.03% | +20.0% |
| Q2 2021 | $527,000 | +7.8% | 1,170 | -8.7% | 0.02% | 0.0% |
| Q1 2021 | $489,000 | +3975.0% | 1,281 | +3271.1% | 0.02% | +733.3% |
| Q4 2020 | $12,000 | -94.8% | 38 | -95.9% | 0.00% | -80.0% |
| Q3 2020 | $230,000 | +45.6% | 930 | +55.3% | 0.02% | +50.0% |
| Q2 2020 | $158,000 | +203.8% | 599 | +119.4% | 0.01% | +150.0% |
| Q1 2020 | $52,000 | -8.8% | 273 | +3.8% | 0.00% | +33.3% |
| Q4 2019 | $57,000 | +9.6% | 263 | -1.9% | 0.00% | 0.0% |
| Q3 2019 | $52,000 | -78.9% | 268 | -77.3% | 0.00% | -82.4% |
| Q2 2019 | $247,000 | +6.0% | 1,181 | 0.0% | 0.02% | -5.6% |
| Q1 2019 | $233,000 | +37.1% | 1,181 | 0.0% | 0.02% | +20.0% |
| Q4 2018 | $170,000 | +17.2% | 1,181 | +66.1% | 0.02% | +36.4% |
| Q3 2018 | $145,000 | -99.6% | 711 | +220.3% | 0.01% | +266.7% |
| Q2 2018 | $32,845,000 | +20300.6% | 222 | -87.6% | 0.00% | -80.0% |
| Q4 2015 | $161,000 | – | 1,786 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |